Cargando…
Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
BACKGROUND: In the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, toxicity of lenvatinib is sometimes considerable and requires frequent dose interruptions and modificati...
Autores principales: | Matsuyama, Chihiro, Enokida, Tomohiro, Ueda, Yuri, Suzuki, Shinya, Fujisawa, Takao, Ito, Kazue, Okano, Susumu, Tahara, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598871/ https://www.ncbi.nlm.nih.gov/pubmed/37886165 http://dx.doi.org/10.3389/fonc.2023.1139659 |
Ejemplares similares
-
Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018) -
Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020) -
A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer
por: Horinouchi, Ai, et al.
Publicado: (2023) -
Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer
por: Shibutani, Yuma, et al.
Publicado: (2023) -
Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)